Inhalable Biologics Market Forecast: Breaking Down The Numbers Behind Future Expansion
Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Inhalable Biologics Market Size, Value And Growth Trajectory Through 2030
The inhalable biologics market size has seen rapid expansion in recent years. Its valuation is set to rise from $3.22 billion in 2025 to $3.73 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 15.7%. This historical growth can be linked to the increasing occurrence of respiratory diseases, the constraints of injectable biologics, progress in inhalation device technology, a developing biologics pipeline, and an uptick in hospital-based respiratory care.
The inhalable biologics market is expected to demonstrate significant expansion in the upcoming years, projected to reach $6.67 billion in 2030 with a compound annual growth rate (CAGR) of 15.6%. This growth during the forecast period is fueled by an increase in chronic respiratory disorders, the extension of inhalable biologics applications beyond respiratory indications, a rising patient preference for non-invasive treatment options, advancements in formulation stability, and heightened investments in pulmonary drug delivery research. Key trends anticipated in the forecast period include the broadening use of pulmonary delivery for systemic biologics, an increasing adoption of dry powder inhalers for biologic drugs, a stronger emphasis on targeted lung drug delivery, the growing development of inhalable monoclonal antibodies, and the integration of patient-friendly, non-invasive biologic therapies.
Get A Free Sample Report With In-Depth Market Insights:
Inhalable Biologics Market Demand Drivers Opening New Revenue Streams
The growing prevalence of respiratory conditions is projected to drive the expansion of the inhalable biologics market in the future. These conditions encompass illnesses and disorders affecting the lungs, airways, and nasal passages within the respiratory system. Their widespread occurrence is linked to rising air pollution, which worsens ailments like asthma, chronic obstructive pulmonary disease (COPD), and lung cancer through exposure to detrimental particulate matter and various pollutants. Inhalable biologics offer advantages for these conditions by providing targeted treatment directly to the lungs, thereby alleviating inflammation and enhancing lung function with reduced systemic adverse effects. For instance, in June 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that in 2023, COPD accounted for 3.6% of the overall disease burden and 50% of the burden from respiratory diseases. Consequently, the rise in respiratory conditions plays a substantial role in the expansion of the inhalable biologics market.
Inhalable Biologics Market Segments: Where Is Growth Concentrated?
The inhalable biologics market covered in this report is segmented –
1) By Type: Peptides And Proteins, Vaccines, Monoclonal Antibodies, RNAi-Based Therapeutics, Other Types
2) By Dosage Form: Dry Powder Inhalers, Metered Dose Inhalers, Nebulizers, Other Dosage Forms
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Respiratory Diseases, Diabetes, Cancer, Other Applications
Subsegments:
1) By Peptides And Proteins: Insulin, Growth Hormones, Enzyme Replacement Therapies, Other Peptides And Proteins
2) By Vaccines: Influenza Vaccines, Other Respiratory Vaccines
3) By Monoclonal Antibodies: Respiratory Monoclonal Antibodies, Immunomodulatory Monoclonal Antibodies, Other Monoclonal Antibodies
4) By RNAi-Based Therapeutics: RNA-Based Drugs For Respiratory Diseases, Other RNAi-Based Therapeutics
5) By Other Types: Gene Therapies, Small Molecule Inhalable Drugs, Other Innovative Inhalable Biologics
Inhalable Biologics Market Trends Powering Strategic Industry Growth
Leading companies operating in the inhalable biologics market are concentrating on developing innovative solutions, such as inhaled insulin, to enhance patient compliance and achieve rapid glycemic control. Inhaled insulin represents a form of insulin administered into the bloodstream through the lungs via inhalation, rather than through injections or insulin pumps. This approach involves inhaling insulin in a powder or aerosolized form, which is then absorbed by the lungs and quickly enters the bloodstream to assist in regulating blood sugar levels. For instance, in February 2025, Cipla Limited, an India-based pharmaceutical company, secured regulatory approval from the Central Drugs Standard Control Organization for Afrezza, recognized as the world’s fastest inhaled insulin, providing a revolutionary, needle-free option for adults with type 1 and type 2 diabetes. This ultra-rapid-acting insulin takes effect within 12 to 15 minutes of inhalation, closely mirroring the natural insulin response to meals and improving blood sugar management. The inhaled insulin offers a more comfortable alternative to multiple daily injections, particularly benefiting patients with injection anxiety and boosting adherence to insulin therapy.
Inhalable Biologics Market Key Participants And Competitive Landscape
Major companies operating in the inhalable biologics market are Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Moderna Inc., Pfizer Inc. and BioNTech SE, Teva Pharmaceuticals, Baxter International, Lonza Group AG, CanSino Biologics Inc., Cipla Ltd., Insmed Incorporated, Kamada Pharmaceuticals, Vectura Group plc, F. Hoffmann‑La Roche Ltd, Iconovo AB, Synairgen plc, Ab Initio Pharma LLC, Nanopharm Ltd, Ocugen Inc., MannKind Corporation
View The Full Inhalable Biologics Market Report:
Inhalable Biologics Market Regional Analysis: Which Geography Leads On Revenue?
North America was the largest region in the inhalable biologics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inhalable biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
